Medial Expression of TNF-α and TNF Receptors Precedes the Development of Atherosclerotic Lesions in Apolipoprotein E/LDL Receptor Double Knockout Mice

	INTRODUCTION

TNF-α is a multifunctional cytokine that plays an important role in immune defense (1, 2). It has also been implicated in pathogenesis of several inflammatory diseases (3, 4). TNF-α shares modes of actions with several other pro-inflammatory cytokines but experiences from treating rheumatoid arthritis patients with TNF-α inhibitors suggests that this cytokine is of unique and critical importance in chronic inflammatory disorders (4, 5).

Several lines of evidence indicate that TNF-α, as well as other inflammatory cytokines, may also be involved in the development of atherosclerosis. TNF-α expressed in skeletal muscle and adipose tissue inhibits phosphorylaTN F expression precedes atherosclerosis developmenttion of the insulin receptor (6-9). By inducing insulin resistance TNF-α may cause metabolic disturbances associated with increased cardiovascular risk, such as low HDL cholesterol levels, hypertriglyceridemia and impaired fibrinolysis (10). Increased plasma levels of TNF-α have been observed in subjects with insulin resistance as well as in patients with early onset of coronary heart disease. Moreover, do the levels correlate with disturbances in the triglyceride as well as glucose metabolism (10, 11).

TNF-α may also have a direct influence on development and progression of atherosclerotic lesions. It is expressed during intimal thickening in humans and in atherosclerotic plaques, and to a lesser extent also in the underlying media (12, 13). Experimental studies have identified several mechanisms by which TNF-α may promote atherogenesis including endothelial adhesion molecule expression (14), activation of macrophages (1), stimulation of smooth muscle cell (SMC) proliferation and migration (15) as well as induction of apoptosis (16). In balloon-injury models of neointima formation, TNF-α is expressed by proliferating SMC (17, 18). Furthermore is the development of transplant atherosclerosis in rabbits inhibited by infusion of TNF-α blocking antibodies (19). In addition, apolipoprotein E (apo E) deficient or apo E/TNF-α double knock-out mice treated with recombinant soluble TNF receptor I releasing pellets demonstrate a significant reduction of lesion size. Almost all of this effect could be retained by only having TNF-α depleted inflammatory cells (20). However, mice lacking either of the TNF p55 or p75 receptors show no evidence of reduced atherosclerosis (21) indicating that the role of TNF-α in atherosclerosis development rewards further investigation. On the other hand, the latter study was performed in a non-atherosclerosis prone animal model (21).

The double knockout mouse model used in the present study lacks both apo E and the low density lipoprotein receptor (apoE^-/-/LDL receptor^-/-). This model has been found to have total cholesterol levels similar to the ones of apo E deficient mice, whereas LDL receptor deficient mice have much lower levels (22). In addition, it develops atherosclerotic plaques sufficiently quickly in the absence of cholesterol-enhanced diet in contrast to both the single knockout mouse models. Furthermore, it has a lipoprotein profile more human than that of the apo E single knockout mouse (22).

So far, mechanism for induction of vascular TNF-α expression has not been fully elucidated. In an established athero-lesion, interferon-γ producing T cells may activate TNF-α expression in surrounding cells. Low levels of oxidized LDL stimulate release of TNF-α from macrophages (23). We have previously demonstrated that a transient accumulation of LDL in rat aorta is associated with induction of TNF-α expression by medial SMC (24). The present study was designed to investigate if vascular TNF-α expression precedes plaque formation in a mouse model of lipid-induced atherosclerosis.

	MATERIAL AND METHODS

Male apolipoprotein E and LDL receptor gene double knockout mice (apoE^-/-/LDL receptor^-/-, n=31) on a C57BL/6 background and C57BL/6 (n=32), were obtained from Bomice (B&M, Aarhus, Denmark). Animals were fed standard R3 chow (AnalyCen, Lidköping, Sweden).

All mice were killed at mid-day by intraperitoneal injection of 150-300 μl hypnorm: dormicum (1:2 parts) and exsanguinated by cardiac puncture on weeks 8, 12, 16 and 20. The blood was immediately placed on ice and allowed to coagulate overnight at 4 °C. Hearts and aortas were surgically removed. Hearts, including the aortic arch and the upper part of descending aorta were washed in 0.9% saline containing 0.02 mM butylated hydroxytoluene (BHT) and fixed in 4% formaldehyde for 12h. For immunohistochemistry, the aortic arch, the thoracic and abdominal regions of the aorta above the renal artery were cut into equal pieces and mounted together in one paraffin block. The abdominal aorta below the renal artery and the common iliac arteries were immediately placed in liquid nitrogen and used for mRNA extraction.

Tissue sections were deparaffinized with xylene and dehydrated with graded ethanol. The membranes were permeabilized in 0.2% Triton X-100. Endogenous peroxidase activity was quenched by incubating the sections in 0.3% H 2 O 2 in 80% methanol for 30 min at room temperature. After washing, sections were blocked with 2-5% rabbit serum in PBS for 30 min. Primary antibodies against TNF-α or TNF receptor p55 and 75 (Santa Cruz Biotechnology) were diluted in PBS (1:100 dilution) and incubated for 16 h at 4 °C in a humidified chamber. Sections were washed and incubated with biotinylated secondary rabbit anti-goat antibody (Vector Laboratories, Burlingame, California) diluted in PBS (1:200 dilution) for 30 min and then washed. The sections were incubated for 30 min with a peroxidase labeled avidin-biotin complex (Vector) and washed again. Sections were developed using DAB detection kit (Vector) and counterstained in hematoxylin. NegaTN F expression precedes atherosclerosis development JUNE 2007 119 tive controls included substitution of the primary antibody with either PBS or irrelevant antibody.

The TNF immunoreactivity was evaluated by image analysis and expressed as percent positive immunostaining of total media or plaque area. A mean medial staining for each animal was calculated based on analyses of 2 sections from the aortic arch, 2 from the descending thoracic aorta and 2 from the abdominal aorta. A mean plaque area for each animal was calculated based on analyses of 6 sections from the aortic arch, 6 from the descending thoracic aorta and 6 from the abdominal aorta.

Cholesterol and triglyceride concentrations in serum were assayed by colorimetric enzymatic techniques (Sigma, St Louis, Missouri). After an overnight incubation at 4 ºC the blood samples were spun at 2000 rpm for 10 minutes after which the plasma was removed and stored at -70 ºC. For analysis, each sample was thawed and diluted (1:10) with PBS and assayed according to instruction using Sigma diagnostics kit.

Total RNA was isolated from the aorta from each mouse using the protocol for FastPrepTM system (BIO 101, Carlsbad, California) with small modifications. A speed rating of 6 for 45 seconds to lyse the aortas was used. The synthesis of cDNA was performed by mixing 1 μg of total RNA with random primers (GibcoBRL, Life Technologies, Gaithersburg, Maryland), DTT (GibcoBRL), dNTP (Boeringer Mannheim, Mannheim, Germany), RNaseINH (Promega, Madison, WI, USA) and Moloney Murine Leukemia Virus Reverse Transcriptase (MMLV-RT) (GibcoBRL). Tubes were incubated for 10 min at 30 °C, 50 min at 42 °C and 2 min at 94 °C.

TaqMan Universal PCR Master Mix (Applied Biosystems, Foster City, California) was used in an ABI PRISM 7700 Sequence Detection System (SDS-Perkin Elmer, Applied Biosystems) for amplification of cDNA according to the manufacturer’s protocol. Samples without MMLV-RT in the cDNA synthesis and wells with no template were used as controls. All samples were run in triplicates. Amplification of TNF-α and 18S rRNA was carried out by using cDNA and TaqMan Pre-developed Assay Reagents (PDARs, Applied Biosystems) and 2x TaqMan Universal PCR Master Mix. Amplification of TNF p55 and p75 receptor was carried out by using appropriate concentrations of specific primer pairs and probes and 2x TaqMan Universal PCR Master Mix. The endogenous control 18S rRNA was used for normalization of data. Calculations were performed using standard curves established by serial dilutions of cDNA synthesized from RNA extracted from aortas of seven months old apoE^-/- mice (B&M).

Values are given as mean ± SD. Differences between groups were calculated using ANOVA. P≤ 0.05 was considered statistical significant.

	RESULTS

One of the aims of the present study was to compare vascular TNF-α and TNF receptor expression in a mouse strain that spontaneously develops atherosclerosis (apoE- /-/LDL receptor^-/- mice) with control mice that does not develop atherosclerosis unless challenged with a high-fat diet (C57BL/6). Plasma triacylglycerol and cholesterol levels in apoE^-/-/LDL receptor^-/- and C57BL/6 mice are presented in table 1. Triacylglycerol levels were 2-3-fold higher and cholesterol levels 4-6-fold higher in the apoE- /-/LDLR^-/- mice than in the control mice. Both triacylglycerol and cholesterol levels increased with age in the double knockout mice.

Vascular TNF p55 and p75 receptor expression was present in all apoE^-/-/LDL receptor^-/- mice already at 8 weeks of age. Expression of TNF-α in the aorta was present in 4 out of 6 double knockout mice at this age. In contrast, no staining for TNF-α or TNF receptors was observed at this age in C57BL/6 mice (Table 2). With only a few exceptions C57BL/6 mice remained negative for TNF-α and TNF receptor immunoreactivity throughout the study. Analysis of the apoE^-/-/LDL receptor^-/- mice demonstrated positive Table 1. Lipid levels in C57BL/6 and apoE^-/-/LDLR^-/- mice Plasma triacylglycerol (mg/mL) Plasma cholesterol (mg/mL) Age (weeks) Control DKO Control DKO 8 2.09 ± 0.64 3.53 ± 0.59** 1.05 ± 0.14 4.57 ± 0.58*** 12 1.83 ± 0.32 5.32 ± 1.92** 1.20 ± 0.10 7.78 ± 0.35*** 16 2.02 ± 0.13 6.65 ± 3.83** 1.30 ± 0.10 8.80 ± 1.75*** 20 1.93 ± 0.47 6.05 ± 2.70*** 1.18 ± 0.14 8.74 ± 2.98*** Control; C57BL/6 mice, DKO; apoE^-/-/LDLR^-/- mice, **P≤0.01 and ***P≤0.001 versus control mice (n=5-6 per group for 8 and 12 weeks old mice and n=10-11 per group for 16 and 20 weeks old mice). TN F expression precedes atherosclerosis development  staining for TNF-α in 27 out of 31 animals and 30 and 29 for the TNF p55 and p75 receptors, respectively (Table 2). The numbers of mice given here are the sum of all time points (8, 12, 16 and 20 weeks of age).

At 8 weeks of age TNF-α immunostaining covered 2.1 ± 1.6% of the aortic media in apoE^-/-/LDL receptor^-/- mice. TNF p55 receptor immunoreactivity covered 5.6 ± 1.5% and TNF p75 receptor immunoreactivity 3.6 ± 1.3% of the media (Figure 1). Aortas of these 8-week old animals did not contain detectable atherosclerotic plaques. At 12 weeks of age, immunoreactivity for TNF-α and TNF receptors had increased only marginally. The expression of immunoreactivity was cell-associated (Figure 2). Atherosclerotic plaques were observed in 1 out of 5 mice. At 16 weeks TNF-α immunoreactivity was increased more than four-fold as compared with 8 weeks (P<0.001) and also the expression of TNF p55 and p75 receptors was significantly increased as compared with 8 week old animals (P<0.01 and P<0.05, respectively; Figure 1). Widespread atherosclerosis was present in most of the 16-week old animals. At 20 weeks, mean plaque size had more than doubled as compared to 16 weeks old mice (Figure 3). The expression of TNF-α and the TNF p55 receptor was also further increased, but not to the same extent as the plaque size (Figure 1). There were no significant differences in the expression of TNF-α or its receptors between animals that had developed detectable atherosclerosis and those that had not.

The expression of TNF-α and TNF receptor immunoreactivity was generally more abundant in plaques than in the media in the double knock-out mice (Table 3). In foam cell-rich lesions of fatty streak-type, TNF-α and TNF receptor were present throughout the entire lesion. In more advanced plaques, TNF-α and TNF receptor immunoreactivity was usually observed in the shoulder region and in the fibrous cap, but not close to the proximity of necrotic cores (Figure 2). In the media, increased expression of TNF-α was often present in SMC located immediately under an advanced plaque (Figure 2).

The amounts of TNF-α mRNA transcripts assessed by Real Time PCR decreased with age in both apoE^-/-/LDL receptor^-/- and control mice (Table 4). In 16-week old mice there was a tendency towards higher TNF-α mRNA levels in the double knock-out mice compared to controls (P=0.06). No significant differences in expression of TNF p55 and TNF p75 receptor mRNA levels were detected in the double knock-out mice compared to controls (Table 4). There was a high variability in the mRNA expression ratios within all groups. This variability may explain the inconsistency between the mRNA expression and the immunohistochemistry staining for TNF p75. A stronger TNF p75 staining was found in apoE^-/-/LDL receptor^-/- mice than in controls (Table 2), whereas no such difference in the mRNA levels was detected (Table 4).

	DISCUSSION

The present study demonstrates that vascular expression of TNF-α and TNF p55 and p75 receptors precedes development of atherosclerotic plaques in apoE^-/-/LDL re- Table 2. Expression of TNF-α and TNF receptors in C57BL/6 and apoE^-/-/LDLR^-/- mice TNF-α TNF p55 receptor TNF p75 receptor Age (weeks) Control DKO Control DKO Control DKO 8 0/6 4/6 0/6 6/6 0/6 6/6 12 3/5 4/5 0/5 4/5 0/5 5/5 16 1/10 10/10 1/10 10/10 3/10 10/10 20 0/11 9/10 0/11 10/10 1/11 8/10 Table shows number of animals with positive immunostaining/total number of animals and group at different time points. Control (C57BL/6) and DKO (apoE^-/-/LDLR^-/-) mice. Figure 1. Percent of media covered by TNF-α and TNF receptor immunoreactivity in apoE^-/-/LDLR^-/- mice. Immunohistochemical staining for TNF-α, TNF p55 and p75 receptors were performed as described in the Methods section. A mean medial staining for each animal was calculated based on analyses of 2 sections from the aortic arch, 2 from the descending thoracic aorta and 2 from the abdominal aorta. Each value represents the mean ± SD of 5 (8 and 12 weeks of age) or 10 (16 and 20 weeks of age) mice. TN F expression precedes atherosclerosis development ceptor^-/- mice. The expression is mainly located in vascular media. The medial TNF-α and TNF receptor expression in apoE^-/-/LDL receptor^-/- mice increased with age and in parallel with progression of lesions with the exception of the TNF p75 receptor that showed decreased staining at 20 weeks. Virtually no TNF-α or TNF receptor immunoreactivity was detected in C57BL/6 control mice. This may be an explanation for why depletion of TNF receptors in this non-atherosclerosis prone mouse model doesn’t fit other observations that TNF-α would be a pro-atherogenic cytokine (21).

A medial expression of TNF-α in non-atherosclerotic arteries of hypercholesterolemic animals such as the apoE- /-/LDL receptor^-/- mouse is well in line with previous studies showing expression of TNF-α mRNA and protein in medial SMC of 6 month old WHHL rabbits (25).Using an animal model in which human LDL is injected intra-venously into rats we have previously shown that accumulation of LDL in rat aorta is associated with enhanced TNF- α mRNA and protein expression within 12 hours (24). At this time point arterial LDL display characteristics specific for oxidative modification (26). However, cell culture experiments suggest that it is native rather than oxidized LDL that is responsible for induction of SMC TNF-α production (24).

Only a sub-population of medial SMC appears to express TNF-α and TNF receptors in response to hypercholesterolemia. Studies in balloon-injured rabbits have pro- Figure 2. Expression of TNF-α and TNF receptor immunoreactivity in the aorta of apoE^-/-/LDLR^-/- mice and C57BL/6 mice. Micrographs demonstrating (A) subendothelial immunostaining of TNF-α in a 12-week old apoE^-/-/LDLR^-/- mouse, (B) absence of TNF-α expression in a 20-week old C57BL/6 mouse, (C) expression of TNF-α throughout the media and (D) in the media and in an atherosclerotic plaque in a 20-week old apoE^-/-/LDLR^-/- mouse, (E) expression of TNF p55 receptor and (F) TNF p75 receptor immunoreactivity in an atherosclerotic plaque in a 20-week old apoE^-/-/LDLR^-/- mouse. Original magnification x 400 in A-C and x 200 in D-F. Table 3. Plaque size, TNF-α and TNFR expression in apoE^-/- /LDLR^-/- mice at 16 and 20 weeks of age 16 weeks 20 weeks Plaque size 43 ± 11.5 97.1 ± 41.4 Media TNF-α 8.2 ± 1.0 9.6 ± 1.2 Media TNF p55 receptor 8.9 ± 1.0 10.0 ± 1.1 Media TNF p75 receptor 7.8 ± 1.1 4.0 ± 0.8 Plaque TNF-α 12.4 ± 2.6 12.3 ± 1.8 Plaque TNF p55 receptor 19.1 ± 4.7 22.6 ± 2.4 Plaque TNF p75 receptor 9.9 ± 3.0 14.8 ± 2.5 Values are presented as mean ± standard deviation of plaque size (x103 μm2) and immunostaining for TNF-α and TNF receptors (% of total media or plaque area) (n=10 per group). Figure 3. Plaque development in apoE^-/-/LDLR^-/- mice. A mean plaque area for each animal was calculated based on analyses of 6 sections from the aortic arch, 6 from the descending thoracic aorta and 6 from the abdominal aorta. Each value represents the mean ± SD of 5 (8 and 12 weeks of age) or 10 (16 and 20 weeks of age) mice. Figure 3. TN F expression precedes atherosclerosis development vided evidence suggesting that medial TNF-α is primarily produced by proliferating SMC (17). It has been proposed that SMC engaged in arterial repair processes and in the formation of atherosclerotic plaques are recruited from a distinct sub-population of medial SMC with increased proliferative capacity (27). Such cells have been isolated from the neointima of balloon-injured rats as well as from normal media (28, 29). It is possible that the TNF- α expressing medial SMC observed in the present study represent such a sub-population of cells. Indeed, we have previously demonstrated that SMC isolated from rat neointima have increased levels of TNF-α and TNF receptors in culture (30). TNF-α does not appear to be involved in the increased rate of proliferation in these cells; instead an endogenous activation of TNF receptors induced cell death by apoptosis limiting the proliferative response.

Previous studies of vascular inflammatory response to hypercholesterolemia have mainly focused on early upregulation of adhesion molecules in the endothelium. Our present findings demonstrate presence of an early inflammatory reaction also in the media. The functional role of this inflammatory response remains to be elucidated, but it is likely to participate in activation of endothelial adhesion molecule expression. One possible scenario is that medial SMC respond to extensive accumulation of native, aggregated or oxidized LDL particles with stimulated TNF secretion resulting in signals to the endothelium to recruit monocytes for modified lipoprotein removal.

In established lesions accumulation of B cells occurs primarily at sites where the surrounding cells express TNF-α and VCAM-1, suggesting that TNF-α-induced expression of adhesion molecules may be of importance for recruitment of mononuclear cells also within plaques (31).

An important question is whether TNF-α in itself plays a critical role in the development of atherosclerosis. This issue is made even more relevant by the recent development of effective TNF-α-inhibitors for use in other chronic inflammatory diseases. TNF-α-inhibition could influence concomitant cardiovascular disease or even be used directly for treatment of atherosclerosis (5). A substantial body of experimental evidence supports the notion that TNF-α has pro-atherogenic effects. It induces endothelial activation (14, 32), stimulates the release of pro-inflammatory cytokines (33) and matrix metalloproteinases (34), activates SMC migration and proliferation (18, 23), inhibits collagen synthesis (35), initiates apoptosis (16) and inhibits fibrinolysis by stimulating the release of plasminogen activator inhibitor (PAI)-1 (36). Animal studies have provided more conflicting results. TNF-α inhibition reduces transplant arteriosclerosis in rabbits (19) and the size of atherosclerotic lesion in apo E deficient mice (20), whereas mice lacking either of the TNF p55 and p75 receptors do not show reduced lesion formation (21). The present observation that vascular expression of TNF-α and TNF receptors precedes plaque formation in this mouse model of atherosclerosis provides some indirect support for a proatherogenic role of TNF-α. The most pronounced increase in medial TNF-α expression occurred at 16 weeks of age, at the same time as the highest TNF-α mRNA levels was detected and as a more wide-spread atherosclerosis began to develop. This may suggest that medial TNF-α expression is actively involved in the disease process, but may also reflect pro-inflammatory effects of plaques on the underlying media.

In summary, this study shows that medial TNF-α and TNF receptor expression precedes lesion formation in the atherosclerosis-susceptible apoE^-/-/LDL receptor^-/- mouse, whereas the aortas of control C57BL/6 mice were essentially negative for TNF-α and TNF receptor immunoreactivity. This suggests that lipid-induced activation of TNF- α expression may play a role in endothelial activation and other inflammatory processes during early stages of atherosclerosis.

View larger version : [in a new window] Figure 1. Percent of media covered by TNF-α and TNF receptor immunoreactivity in apoE-/-/LDLR-/- mice. Immunohistochemical staining for TNF-α, TNF p55 and p75 receptors were performed as described in the Methods section. A mean medial staining for each animal was calculated based on analyses of 2 sections from the aortic arch, 2 from the descending thoracic aorta and 2 from the abdominal aorta. Each value represents the mean ± SD of 5 (8 and 12 weeks of age) or 10 (16 and 20 weeks of age) mice.

 

View larger version : [in a new window] Figure 2. Expression of TNF-α and TNF receptor immunoreactivity in the aorta of apoE-/-/LDLR-/- mice and C57BL/6 mice. Micrographs demonstrating (A) subendothelial immunostaining of TNF-α in a 12-week old apoE-/-/LDLR-/- mouse, (B) absence of TNF-α expression in a 20-week old C57BL/6 mouse, (C) expression of TNF-α throughout the media and (D) in the media and in an atherosclerotic plaque in a 20-week old apoE-/-/LDLR-/- mouse, (E) expression of TNF p55 receptor and (F) TNF p75 receptor immunoreactivity in an atherosclerotic plaque in a 20-week old apoE-/-/LDLR-/- mouse. Original magnification x 400 in A-C and x 200 in D-F.

 

View larger version : [in a new window] Figure 3. Plaque development in apoE-/-/LDLR-/- mice. A mean plaque area for each animal was calculated based on analyses of 6 sections from the aortic arch, 6 from the descending thoracic aorta and 6 from the abdominal aorta. Each value represents the mean ± SD of 5 (8 and 12 weeks of age) or 10 (16 and 20 weeks of age) mice.

	ACKNOWLEDGEMENTS

We thank Valerie Defaweux for expert technical assistance. This study was supported by grants from the Swedish Medical Research Council, the Swedish Heart-Lung foundation, the King Gustaf V 80th Birthday foundation, Table 4. TNF-α and TNFR mRNA expression in apoE^-/-/LDLR^-/- mice TNF-α TNF p55 receptor TNF p75 receptor Age (weeks) Control DKO Control DKO Control DKO 16 852 ± 987 3005 ± 1998 468 ± 326 392 ± 270 1495 ± 1245 412 ± 433 20 106 ± 174 52 ± 74 462 ± 355 1511 ± 2856 1174 ± 884 232 ± 229 Values are given as the ratio of TNF-α or TNF receptor mRNA expression, respectively, and 18S rRNA expression. Control; C57BL/6 mice, DKO; apoE^-/-/LDLR^-/- mice (n=10-11 per group). TN F expression precedes atherosclerosis development the Bergqvist foundation, the Tore Nilsson foundation, the Crafoord foundation, the Swedish Society of Medicine, the Royal Physiographic Society, Malmö University Hospital foundation and the Lundström foundation.

	CONFLICT OF INTEREST STATEMENT

    The authors declare that no conflicting interests exist.

	REFERENCES

• 1. Vassalli P. The pathophysiology of tumor necrosis factors. Ann Rev Immunol. 1992; 10: 411-452.
• 2. Bazzoni F, Beutler B. The tumor necrosis factor ligand and receptor families. N Eng J Med. 1996; 331: 1717-1725.

• 3. Papadakis K, Targan S. Role of cytokines in inflammatory bowel dis¬eases. Ann Rev Med. 2000; 51: 289-298.

• 4. Maini R, Taylor P. Anti-cytokine therapy for rheumatoid arthritis. Ann Rev Med. 2000; 51: 207-229.
• 5. Sarzi-Puttini P, Atzeni F, Doria A, et al. Tumor necrosis factor-alpha, biologic agents and cardiovascular risk. Lupus. 2005; 14: 780-784.
• 6. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-α: direct role in obesity-linked insulin resis¬tance. Science. 1993; 259: 87-91.
• 7. Saghizadeh M, Ong JM, Garvey WT, et al. The expression of TNFα by human muscle. Relationship to insulin resistance. J Clin Invest. 1996; 97: 1111-1116.
• 8. Kern PA, Saghizadeh M, Ong JM, et al. The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest. 1995; 95: 2111-2119.
• 9. Kanety H, Feinstein R, Papa MZ, et al. Tumor necrosis factor α¬induced phosphorylation of the insulin receptor substrate-1 (IRS-1). J Biol Chem. 1995; 270: 23780-23784.
• 10. Hotamisligil GS, Spiegelman BM. Tumor necrosis factor α: A key component of the obesity-diabetes link. Diabetes. 1994; 43: 1271-1278.
• 11. Jovinge S, Hamsten A, Tornvall P, et al. Evidence for a role of tumor necrosis factor-α in disturbances of triglyceride and glucose metabo¬lism predisposing to coronary heart disease. Metabolism. 1998; 47: 113-118.
• 12. Barath P, Fishbein M, Cao J, et al. Detection and localization of tumour necrosis factor in human atheroma. Am J Pathol. 1990; 65: 297-302.
• 13. Rus H, Niculescu F, Vlaicu R. Tumor necrosis factor-alpha in human arterial wall with atherosclerosis. Atherosclerosis. 1991; 89: 247-254.
• 14. Bevilaacqua M, Stengelin S, Gimbrone M, et al. Endothelial leukocyte adhesion molecule-1: an inducible receptor for neutrophils related to complement regulatory proteins and lectins. Science. 1989; 243: 1467-1469.
• 15. Jovinge S, Hultgårdh-Nilsson A, Regnström J, et al. Smooth muscle cell migration and cytoskeletal rearrangements in response to tumor necrosis factor α. Arterioscler Thromb Vasc Biol. 1997; 17: 490-497.
• 16. Geng YJ, Wu Q, Muszynski M, et al. Apoptosis of vascular smooth muscle cells induced by in vitro stimulation with interferon-gamma, tumor necrosis factor-alpha, and interleukin-1 beta. Arterioscler Thromb Vasc Biol. 1996; 16: 19-27.
• 17. Tanaka H, Sukhova G, Schwartz D, et al. Proliferating arterial smooth muscle cells after ballon injury express TNF-alpha but not interleu¬kin-1 or basic fibroblast growth factor. Arterioscler Thromb VascBiol.1996; 16: 12-18.
• 18. Jovinge S, Hultgårdh-Nilsson A, Regnström J, et al. Tumor Necrosis Factor alpha activates smooth muscle cell migration in culture and is expressed in the balloon-injured rat aorta. Arterioscler Thromb Vasc Biol. 1997; 17: 490-497.
• 19. Clausell N, Molossi S, Sett S, et al. In vivo blockade of tumor necro¬sis factor-α in cholesterol-fed rabbits after cardiac transplant inhibits acute coronary artery neointimal formation. Circulation. 1994; 89: 2768-2779.
• 20. Branen L, Hovgaard L, Nitulescu M, et al. Inhibition of tumor necro¬sis factor-alpha reduces atherosclerosis in apolipoprotein E knockout mice. Arterioscler Thromb Vasc Biol. 2004; 24: 2137-42.
• 21. LeBoeuf R, Schreyer S. The role of tumor necrosis factor-α receptors in atherosclerosis. Trends in Cardiovasc Med. 1998; 8: 131-138.
• 22. Ishibashi S, Herz J, Maeda N, et al. The two-receptor model of lipopro¬tein clearance: tests of the hypothesis in "knockout" mice lacking the low density lipoprotein receptor, apolipoprotein E, or both proteins. Proc Natl Acad Sci U S A. 1994; 91: 4431-5.
• 23. Jovinge S, Ares M, Kallin B, et al. Human monocytes/Macrophages release TNF-α in response to ox-LDL. Arterioscler Thromb Vasc Biol. 1997; 16: 1573-1579.
• 24. Niemann-Jönsson A, Dimayuga P, Jovinge S, et al. Accumulation of low density lipoprotein in rat arteries is associated with activa¬tion of tumor necrosis factor-α expression. Arterioscler Thromb Vasc Biol.2000; 20: 2205-2211.
• 25. Lei X, Buja L. Detection and localization of tumor necrosis factor¬alpha in WHHL rabbit arteries. Atherosclerosis. 1996; 125: 81-89.
• 26. Calara F, Dimayuga P, Niemann A, et al. An animal model to study local oxidation of LDL and its biological effects in the arterial wall. Arterioscler Thromb Vasc Biol. 1998; 18: 884-893.
• 27. Schwartz S, Murray C. Proliferation and the monoclonal origins of atherosclerotic lesions. Ann Rev Med. 1998; 49: 437-460.
• 28. Bochaton-Piallat M, Gabbiani F, Gabbiani G. Heterogeneity of rat aortic smooth muscle cell replication during development: correlation with replicative activity after experimental endothelial denudation in adults. J Submicrosc Cytol Pathol. 1994; 26: 1-8.
• 29. Villaschi S, Nicosia R, Smith M. Isolation of a morphologically and functionally distinct smooth muscle cell type from the intimal aspect of the normal rat aorta. Evidence for smooth muscle cell heterogeneity. In Vitro Cell Dev Biol. 1994; 30A: 589-595.
• 30. Niemann-Jonsson A, Ares MP, Yan ZQ, et al. Increased rate of apopto¬sis in intimal arterial smooth muscle cells through endogenous activa¬tion of TNF receptors. Arterioscler Thromb Vasc Biol. 2001; 21: 1909-14.
• 31. Zhou X, Hansson G. Detection of B cells and proinflammatory cyto¬kines in atherosclerotic plaques of hypercholesterolaemic apolipopro¬tein E knockout mice. Scand J Immunol. 1999; 50: 25-30.
• 32. Gamble J, Harlan J, Klebanoff S, et al. Stimulation of the adherence of neutrophils to umbilical vein endothelium by hyman recombinant tumor necrosis factor. Proc Nat Acad Sci USA. 1985; 82: 8667-8671.
• 33. Warner SJC, Libby P. Human smooth muscle cells. Target and source of tumor necrosis factor. J Immunol. 1989; 142: 100-109.
• 34. Galis ZS, Sukhova GK, Lark MW, et al. Increased expression of matrix metalloproteinases and matrix degrading activity in vulner¬able regions of human atherosclerotic plaques. J Clin Invest. 1994; 94: 2493-2503.
• 35. Siwik D, Chang D, Colucci W. Interleukin-beta and tumor necrosis factor-alpha decrease collagen synthesis and matrix metalloproteinase activity in fibroblasts in vitro. Circ Res. 2000; 86: 1259-1265.
• 36. Sawdey M, Podor T, Loskutoff D. Regulation of type 1 plasminogen activator inhibitor gene expression in cultured bovine aortic endothe¬lial cells. J Biol Chem. 1989; 264: 10396-10401.

The exquisite patterns on the luxury replica watches dial, the date display window at replica watches six o'clock, and the black sculpted Arabic numerals demonstrate the replica rolex exquisite craftsmanship of rolex watches uk the fine watchmaking style.